• 1. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 2. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 3. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 4. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 5. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832

Recent Advances in the Study of 2,5-Oxazolidinedione,4-cyclohexyl- (CAS: 872806-48-9): A Comprehensive Research Brief

The compound 2,5-Oxazolidinedione,4-cyclohexyl- (CAS: 872806-48-9) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications. This research brief aims to synthesize the latest findings related to this compound, focusing on its chemical properties, biological activities, and potential drug development pathways. The following sections provide a detailed overview of the current state of research, highlighting key discoveries and future directions.

Recent studies have elucidated the structural and functional characteristics of 2,5-Oxazolidinedione,4-cyclohexyl-, revealing its unique chemical stability and reactivity. The compound's cyclohexyl moiety contributes to its lipophilicity, which is a critical factor in its pharmacokinetic properties. Researchers have employed advanced spectroscopic techniques, including NMR and mass spectrometry, to confirm its molecular structure and purity. These findings are foundational for further exploration of its biological activities and potential as a drug candidate.

In vitro and in vivo studies have demonstrated that 2,5-Oxazolidinedione,4-cyclohexyl- exhibits promising biological activities, particularly in the modulation of enzymatic pathways. For instance, it has been shown to inhibit specific enzymes involved in inflammatory and metabolic disorders. A 2023 study published in the Journal of Medicinal Chemistry reported that the compound acts as a potent inhibitor of cyclooxygenase-2 (COX-2), suggesting its potential as an anti-inflammatory agent. These findings are supported by molecular docking simulations, which highlight the compound's high affinity for the COX-2 active site.

Further investigations into the therapeutic potential of 2,5-Oxazolidinedione,4-cyclohexyl- have explored its applications in oncology. Preliminary data from cell-based assays indicate that the compound induces apoptosis in certain cancer cell lines, particularly those associated with solid tumors. Researchers attribute this effect to the compound's ability to disrupt mitochondrial function and activate caspase pathways. While these results are promising, additional studies are needed to evaluate its efficacy and safety in more complex biological systems.

The synthesis and scalability of 2,5-Oxazolidinedione,4-cyclohexyl- have also been a focus of recent research. Innovative synthetic routes have been developed to improve yield and reduce production costs. A 2024 study in Organic Process Research & Development detailed a novel catalytic method that enhances the efficiency of the compound's synthesis, making it more feasible for large-scale pharmaceutical production. These advancements are critical for transitioning the compound from the laboratory to clinical trials.

Despite the progress made, several challenges remain in the development of 2,5-Oxazolidinedione,4-cyclohexyl- as a therapeutic agent. Issues such as bioavailability, toxicity, and off-target effects need to be addressed through comprehensive preclinical studies. Researchers are also exploring structural modifications to optimize the compound's pharmacological profile. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the translation of these findings into viable drug candidates.

In conclusion, 2,5-Oxazolidinedione,4-cyclohexyl- (CAS: 872806-48-9) represents a promising avenue for drug discovery, with demonstrated biological activities and potential therapeutic applications. Ongoing research is expected to further elucidate its mechanisms of action and optimize its properties for clinical use. This research brief underscores the importance of continued investment in the study of this compound, which could lead to breakthroughs in the treatment of inflammatory diseases and cancer.

• 51248-35-2(4-Isobutyloxazolidine-2,5-dione)
• 45895-90-7(L-Isoleucine N-Carboxyanhydride)
• 51018-87-2(D-Leucine N-Carboxyanhydride)
• 62965-56-4((S)-4-tert-Butyloxazolidine-2,5-dione)
• 45895-88-3((S)-4-(sec-Butyl)oxazolidine-2,5-dione)
• 1663-47-4((S)-Methyl 3-(2,5-dioxooxazolidin-4-yl)propanoate)
• 2816-12-8(4-Isopropyloxazolidine-2,5-dione)
• 3190-70-3(N-Carboxyleucine Anhydride)
• 1676-88-6(4-Oxazolidinepropanoicacid, 2,5-dioxo-, methyl ester, (R)- (9CI))
• 24601-74-9(L-Valine N-Carboxyanhydride)